The role of the interaction between endogenous opioids and nitric oxide in the pathophysiology of ethanol-induced gastric damage in cholestatic rats

Fundam Clin Pharmacol. 2001 Jun;15(3):181-7. doi: 10.1046/j.1472-8206.2001.00028.x.

Abstract

Interaction between endogenous opioids and nitric oxide (NO) has been shown in different biological models and pharmacological evidence suggest that opioids can induce NO release in endothelium as well as in neural cells. Cholestasis is associated with NO overproduction. The reason for increased NO synthesis is not clearly known but it can potentiate development of gastric mucosal damage in cholestatic subjects. Based on increased plasma levels of endogenous opioids and existence of NO overproduction in cholestasis, the present experiments were performed to investigate the role of interaction between endogenous opioids and NO in generation of ethanol-induced gastric damage in cholestatic rats. Cholestasis was induced by surgical ligation of bile duct and sham-operated rats served as controls. The animals received either 20 mg/kg of naltrexone or saline for 6 days and then were fasted and received L-arginine (200 mg/kg), NG-nitro-L-arginine methylester (L-NAME; 2, 5 and 10 mg/kg) or saline. The ethanol-induced gastric mucosal damage was significantly more severe in cholestatic rats than in sham-operated animals (115 +/- 12 mm2 vs. 72 +/- 11 mm2, P < 0.05). L-NAME significantly enhanced the development of gastric mucosal lesions in sham-operated rats. But in cholestatic animals, L-NAME decreased and L-arginine enhanced the severity of gastric damage. Pretreatment of animals with naltrexone decreased severity of gastric mucosal damage in cholestatic rats. Concurrent administration of naltrexone with L-arginine was protective against ethanol-induced gastric damage in both normal and cholestatic groups. Administration of naltrexone with L-NAME had the same effect in cholestatic and control rats and increased severity of gastric damage. Plasma levels of NO2- + NO3- were significantly higher in cholestatic rats than control animals (72 +/- 6 microM vs. 39 +/- 3 microM, P < 0.05). Pretreatment of animals with naltrexone significantly reduced plasma levels of NO2- + NO3- in cholestatic animals, but not in control rats (33 +/- 6 microM vs. 32 +/- 4 microM). The protective effect of L-NAME against gastric damage in cholestatic rats can be explained by inhibition of NO overproduction and it seems that interaction between opioids and NO may have an important role in generation of NO overproduction and gastric complications in cholestatic rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alcohol Deterrents / pharmacology
  • Animals
  • Arginine / pharmacology
  • Bile Ducts / surgery
  • Cholestasis / chemically induced
  • Disease Models, Animal
  • Enzyme Inhibitors / pharmacology
  • Ethanol / toxicity*
  • Gastric Mucosa / drug effects*
  • Gastric Mucosa / pathology
  • Ligation
  • Male
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Naltrexone / analogs & derivatives
  • Naltrexone / pharmacology
  • Narcotic Antagonists / pharmacology
  • Nitrates / blood
  • Nitric Oxide / antagonists & inhibitors
  • Nitric Oxide / physiology*
  • Nitrites / blood
  • Opioid Peptides / physiology*
  • Rats
  • Stomach Ulcer / chemically induced
  • Stomach Ulcer / etiology*

Substances

  • Alcohol Deterrents
  • Enzyme Inhibitors
  • Narcotic Antagonists
  • Nitrates
  • Nitrites
  • Opioid Peptides
  • Nitric Oxide
  • Ethanol
  • Naltrexone
  • naltrexazone
  • Arginine
  • NG-Nitroarginine Methyl Ester